Research Funding Opportunities
2013 RFA CONCEPTS CLOSED
Concept Due Date: May 24, 2013
Full Applications Due: August 9, 2013
Funding to begin January 2014
The Lustgarten Foundation (LF) is the nation’s largest private funder of pancreatic cancer research. Our mission is to advance scientific and medical research related to the diagnosis, treatment, cure and prevention of pancreatic cancer. Thanks to the support of Cablevision, 100% of all our donations go directly to research, which has enabled us to commit $65 Million to outstanding research projects to date.
For the 2013 Grant application cycle, The Foundation’s Scientific Review Board has identified a number of research areas for which proposals are now being solicited (below).
How to Apply/Deadlines
The LF has modified its application process to allow for electronic concept and full application submission. Information on how to use this site can be found in our Applicant Tutorial.
- Before you submit your letter of intent and application, download and read our Policies and Instructions. To apply, you must log in to the LF application webpage and register.
- Submit an online letter of intent via the LF application webpage by 5 p.m. ET, May. 24, 2013.
- A subset of the proposals will be selected to submit a full proposal for in-depth consideration. These selected investigators will be notified, by July 12th, 2013
- Full applications should be submitted via the LF application webpage by 5 p.m. ET, August 9, 2013.
Early Detection and Risk Assessment in Pancreas Cancer
New Drug Delivery Approaches in Pancreas Cancer
Novel Imaging Technologies in Pancreas Cancer
Novel Therapeutic Agents in Pancreas Cancer
Correlative Studies Awards Program
Novel Agents for Pancreas Cancer
Clinical and Molecular Markers of Metastic Burden
Immune Surveillance and Modulation
Early Stage Target Validation for Pancreas Cancer
Impact of Chromatin Alteration in Pancreas Cancer
New Models of PDAC
The Foundation is always interested in new “out of the box” ideas that have the potential of significantly impacting the lives of pancreas cancer patients. Concepts addressing the following areas will be considered and can be submitted via the LF Application webpage under Clinical , Preclincial or Basic “Other” categories.
- Prevention Studies – that elucidate the factors that increase or decrease pancreatic cancer incidence, using either epidemiologic or experimental approaches in model systems or in humans.
- Innovative therapies where–
- The approach does not violate basic physico-chemical principles.
- The approach does not closely resemble those that have failed before in the treatment of cancers, including pancreatic cancers.
- The approach could be developed and tested in experimental animals within a reasonable time frame.
- The approach is cognizant of the difficulties previously encountered in the treatment of pancreatic cancers in humans.
- The approach is feasible in principle and could eventually be applied to humans without causing incapacitating side effects that can easily be anticipated.